drugset / Trial / NCT00651612

Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients

NCT00651612

Phase 3 Completed 604 enrolled Allergan
RandomizedParallel-groupDouble-blindTreatment

Summary

This study evaluates the safety of brimonidine/timolol fixed combination in glaucoma or ocular hypertension patients

Timeline

Start
2005-11
Primary completion
2007-01
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Brimonidine Small molecule 0.2 % Other
Subject Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution Unknown 0.2 % Other
Subject Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution Unknown 0.5 % Other
Comparator Timolol Other / unclassified 0.5 % Other